A biopharmaceutical company discovering and developing small-molecule therapeutics for neurological and psychiatric conditions
A biopharmaceutical company discovering and developing small-molecule therapeutics for neurological and psychiatric conditions. Its lead late-stage clinical program, AGB101, targets hippocampal overactivity to prevent or delay progression from amnestic mild cognitive impairment due to Alzheimer’s disease to Alzheimer’s dementia. The company also has a GABA(A) alpha5 small-molecule discovery program with potential applications in amnestic mild cognitive impairment, autism, and schizophrenia.